



**COMMONWEALTH OF KENTUCKY  
 CABINET FOR HEALTH AND FAMILY SERVICES  
 DEPARTMENT FOR MEDICAID SERVICES  
 PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

**NOTE: This special called meeting will be held virtually via Microsoft Teams webinar.**  
 Tuesday, July 9, 2024  
 1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In
<a href="#">Join the meeting now</a>  Meeting ID: 298 189 115 587 Passcode: YjuBYV  <a href="#">Download Teams</a>   <a href="#">Join on the web</a>	+1-858-252-2734 (US Toll)  Phone Conference ID: 703 962 952#

## AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
  - a. Approval of April 2024 Meeting Minutes
- IV. New Business**
  - a. New Products to Market to be Reviewed as Single Products:
    - i. Opsyngvi® (*Pulmonary Arterial Hypertension (PAH) Agents, Oral and Inhaled*)
    - ii. Winrevair™ (*Non-PDL*)
    - iii. Voydeya™ (*Non-PDL*)
    - iv. Rivfloza™ (*Non-PDL*)
    - v. Zymfentra™ (*Cytokine and CAM Antagonists*)
    - vi. Filsuvez® (*Non-PDL*)
    - vii. Eohilia™ (*Non-PDL*)
    - viii. Alvaiz™ (*Thrombopoiesis Stimulating Proteins*)
    - ix. Rezdiffra™ (*Non-PDL*)
- V. Therapeutic Classes with Recommended Changes**
  - a. Angiotensin-Converting Enzyme (ACE) Inhibitors + Diuretic Combinations
  - b. Angiotensin Modulator + Calcium Channel Blocker Combinations
  - c. Antiarrhythmics, Oral
  - d. Antidepressants, SNRIs
  - e. Antidepressants, SSRIs
  - f. Beta-Blockers
  - g. Calcium Channel Blockers
  - h. Narcolepsy Agents
  - i. Pulmonary Arterial Hypertension Agents – Oral and Inhaled



V. Therapeutic Classes with Recommended Changes (continued)

- j. Sedative Hypnotics
- k. Stimulants and Related Agents

VI. Consent Agenda

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> <li>• Angiotensin-Converting Enzyme (ACE) Inhibitors</li> <li>• Angiotensin Receptor Blockers (ARBs)</li> <li>• Antianginal &amp; Anti-Ischemic</li> <li>• Anticoagulants</li> <li>• ARB + Diuretic Combinations</li> <li>• Direct Renin Inhibitors</li> <li>• Lipotropics, Other</li> <li>• Lipotropics, Statins</li> <li>• Platelet Aggregation Inhibitors</li> <li>• Alzheimer’s Agents</li> <li>• Anticonvulsants</li> <li>• Antidepressants, Monoamine Oxidase Inhibitors (MAOIs)</li> </ul>	<ul style="list-style-type: none"> <li>• Antidepressants, Other</li> <li>• Antidepressants, Tricyclics</li> <li>• Antiparkinson’s Agents</li> <li>• Dopamine Receptor Agonists</li> <li>• Antipsychotics</li> <li>• Anxiolytics</li> <li>• Movement Disorders</li> <li>• Tobacco Cessation Products</li> <li>• 5-Alpha Reductase Inhibitors</li> <li>• Alpha Blockers for Benign Prostatic Hyperplasia (BPH)</li> <li>• Bladder Relaxants</li> </ul>
--	--

VII. Adjournment

- a. Schedule of Upcoming Meetings
  - i. **October 17, 2024**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.